Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.
From new forms of PrEP to new data on HIV in the U.S., CROI 2021 has plenty of developments to report when it comes to preventing HIV and better understanding the drivers of the modern epidemic.
Arriving on the one-year anniversary of nationwide COVID-19 shutdowns, the 2021 Conference on Retroviruses and Opportunistic Infections won't be in person this year—but it will emphasize COVID-19 alongside important HIV prevention and treatment updates.
A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
HIV and TB often go hand in hand among people experiencing homelessness in the U.S.—a reality that gives public health officials an opportunity to utilize shelters in tackling both viruses at the same time.
Open conversations between care providers and Black women are vitally important in order to empower women with information about HIV and how to protect their health.